It was announced on Thursday 24 October that Symkevi, Orkambi and Kalydeco will be made available to all eligible cystic fibrosis patients after a deal was struck between NHS England and the manufacturer, Vertex.
This is amazing news and we are incredibly pleased for our patients.
We also remain very hopeful for further research developments which will allow all our patients access to CFTR modulator therapies.
We have already started planning the initiation of all eligible patients on these medications but are currently awaiting further guidance from the NHS.
We are working hard to ensure patients who are eligible will have access to these medications as soon as possible and we will keep you informed through your regular clinic appointments and when you attend the hospital.